A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

NCT04626674 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscular Dystrophy, Duchenne

Interventions

GENETIC: delandistrogene moxeparvovec

Sponsor

Sarepta Therapeutics, Inc.

Collaborators

[object Object]